INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
EClinicalMedicine
December 2020
Nature Communications
May 2020
The New England Journal of Medicine
October 2017
The Lancet Infectious Diseases
July 2019
The Journal of Infectious Diseases
March 2019
| Title | Disease Target | Product |
|---|---|---|
| Electroporation delivery of DNA vaccines: prospects for success Current Opinion in Immunology — June 2011 | Delivery | CELLECTRA® |
| A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle Vaccine — September 2011 | Delivery | CELLECTRA |
| Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses Vaccine — June 2019 | Delivery | CELLECTRA |
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2021 INOVIO Pharmaceuticals. All rights reserved.
